DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results

DiaMedica Therapeutics (NASDAQ:DMAC) released its earnings results on Monday. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01), Zacks reports.

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC traded up $0.22 during mid-day trading on Monday, hitting $5.99. 106,512 shares of the company’s stock were exchanged, compared to its average volume of 69,604. The company has a market cap of $256.14 million, a PE ratio of -10.70 and a beta of 1.52. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $6.82. The business has a fifty day moving average price of $5.95 and a 200 day moving average price of $5.08.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.